Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
XOMA (US) LLC |
---|---|
Information provided by: | XOMA (US) LLC |
ClinicalTrials.gov Identifier: | NCT00034203 |
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
Condition | Intervention | Phase |
---|---|---|
Rheumatoid Arthritis |
Drug: efalizumab |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Exclusion criteria:
Study ID Numbers: | HURA501 |
Study First Received: | April 23, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00034203 |
Health Authority: | United States: Food and Drug Administration |
Antibodies, Monoclonal Antibodies Autoimmune Diseases Musculoskeletal Diseases Joint Diseases |
Arthritis Connective Tissue Diseases Arthritis, Rheumatoid Rheumatic Diseases Immunoglobulins |
Immune System Diseases |